A dynamic transmission model for assessing the impact of pneumococcal vaccination in the United States
Related Experiment Video
Updated: May 17, 2025
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Tufail M Malik1, Kevin M Bakker1, Rachel J Oidtman1
1Merck & Co., Inc., Rahway, New Jersey, United States of America.
Insights
Introducing PCV15, a new pneumococcal conjugate vaccine (PCV), can reduce invasive pneumococcal disease (IPD) by over 6% in 10 years. This vaccine offers broader serotype coverage, addressing serotype replacement challenges.
Area of Science:
- Epidemiology
- Immunology
- Public Health
Background:
- Streptococcus pneumoniae (SP) causes significant global child mortality, necessitating effective vaccination strategies.
- Pneumococcal conjugate vaccines (PCVs) reduce disease but can lead to serotype replacement, where non-vaccine types increase.
- Understanding serotype dynamics is crucial for optimizing vaccine impact.
Purpose of the Study:
- To evaluate the population-level impact of introducing PCV15 in the pediatric population.
- To assess the benefits of PCV15's expanded serotype coverage compared to existing PCV13.
- To model the dynamics of pneumococcal carriage and invasive pneumococcal disease (IPD) considering co-colonization and serotype competition.
Main Methods:
- An age-structured compartmental model was developed and calibrated using historical US invasive pneumococcal disease (IPD) data.
- The model incorporated co-colonization, serotype competition, and age-specific population mixing patterns.
- Vaccine effectiveness, coverage, and demographic data were integrated to simulate the impact of PCV15 versus PCV13.
Main Results:
- PCV15 introduction is projected to reduce overall IPD incidence by 6.04% over a 10-year period compared to PCV13.
- The model successfully reproduced historical pneumococcal transmission dynamics and serotype replacement phenomena.
- The added serotypes in PCV15 are demonstrated to provide significant public health benefits.
Conclusions:
- PCV15 offers a valuable advancement in pneumococcal disease prevention by covering additional serotypes.
- The expanded coverage of PCV15 is expected to further reduce the burden of IPD, mitigating serotype replacement.
- Mathematical modeling provides a robust framework for predicting the epidemiological impact of new vaccine introductions.
Abstract:
Streptococcus pneumoniae (SP) is a bacterial pathogen that kills more than 300,000 children every year across the globe. Multiple vaccines exist that prevent pneumococcal disease, with each vaccine covering a variable number of the more than 100 known serotypes. Due to the high effectiveness of these vaccines, each new pneumococcal conjugate vaccine (PCV) introduction has resulted in a decrease in vaccine-type disease and a shift in the serotype distribution towards non-vaccine types in a phenomenon called serotype replacement. Here, an age-structured compartmental model was created that reproduced historical carriage transmission dynamics in the United States and was used to evaluate the population-level impact of new vaccine introductions into the pediatric population. The model incorporates co-colonization and serotype competition, which drives replacement of the vaccine types by the non-vaccine types. The model was calibrated to historical age- and serotype-specific invasive pneumococcal disease (IPD) data from the United States. Vaccine-specific coverage and effectiveness were integrated in accordance with the recommended timelines for each age group. Demographic parameters were derived from US-population-specific databases, while population mixing patterns were informed by US-specific published literature on age-group based mixing matrices. The calibrated model was then used to project the epidemiological impact of PCV15, a 15-valent pneumococcal vaccine, compared with the status quo vaccination with PCV13 and demonstrated the value of added serotypes in PCV15. Projections revealed that PCV15 would reduce IPD incidence by 6.04% (range: 6.01% to 6.06%) over 10 years when compared to PCV13.
Related Concept Videos
01:51Vaccinations
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:30Pneumonia III: Complications and Assessment
01:23Mechanistic Models: Compartment Models in Individual and Population Analysis
01:18Models of Health Promotion and Illness Prevention II
The agent-host-environment model states that disease results...